The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Monteiro, A. C.
Right arrow Articles by Scharfstein, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Monteiro, A. C.
Right arrow Articles by Scharfstein, J.
The Journal of Immunology, 2006, 177: 6325-6335.
Copyright © 2006 by The American Association of Immunologists, Inc.

Cooperative Activation of TLR2 and Bradykinin B2 Receptor Is Required for Induction of Type 1 Immunity in a Mouse Model of Subcutaneous Infection by Trypanosoma cruzi1

Ana Carolina Monteiro*, Verônica Schmitz*, Erik Svensjo*, Ricardo T. Gazzinelli{dagger},{ddagger}, Igor C. Almeida§, Alex Todorov*, Luciana B. de Arruda, Ana Cláudia T. Torrecilhas||, João B. Pesquero#, Alexandre Morrot**, Eliete Bouskela{dagger}{dagger}, Adriana Bonomo, Ana Paula C. A. Lima*, Werner Müller-Esterl* and Julio Scharfstein2,*

* Instituto de Biofisica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil; {dagger} Laboratório de Imunopatologia, Centro de Pesquisas René Rachou-Fiocruz, Belo Horizonte, Brazil; {ddagger} Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil; § Department of Biological Sciences, University of Texas, El Paso, TX 79968; Instituto de Microbiologia, UFRJ, Rio de Janeiro, Brazil; || Departamento de Bioquimica, Universidade de São Paulo, São Paulo, Brazil; # Departmento de Biofisica, Universidade Federal de São Paulo, São Paulo, Brazil; ** Department of Molecular Microbiology and Immunology, Johns Hopkins University, Baltimore, MD 21205; {dagger}{dagger} Laboratório de Microcirculação, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil; and * Institute of Biochemistry II, University of Frankfurt Medical School, Frankfurt, Germany


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
We have previously reported that exogenous bradykinin activates immature dendritic cells (DCs) via the bradykinin B2 receptor (B2R), thereby stimulating adaptive immunity. In this study, we show that these premises are met in a model of s.c. infection by Trypanosoma cruzi, a protozoan that liberates kinins from kininogens through its major protease, cruzipain. Intensity of B2R-dependent paw edema evoked by trypomastigotes correlated with levels of IL-12 produced by CD11c+ dendritic cells isolated from draining lymph nodes. The IL-12 response induced by endogenously released kinins was vigorously increased in infected mice pretreated with inhibitors of angiotensin converting enzyme (ACE), a kinin-degrading metallopeptidase. Furthermore, these innate stimulatory effects were linked to B2R-dependent up-regulation of IFN-{gamma} production by Ag-specific T cells. Strikingly, the trypomastigotes failed to up-regulate type 1 immunity in TLR2–/– mice, irrespective of ACE inhibitor treatment. Analysis of the dynamics of inflammation revealed that TLR2 triggering by glycosylphosphatidylinositol-anchored mucins induces plasma extravasation, thereby favoring peripheral accumulation of kininogens in sites of infection. Further downstream, the parasites generate high levels of innate kinin signals in peripheral tissues through the activity of cruzipain. The demonstration that the deficient type 1 immune responses of TLR2–/– mice are rescued upon s.c. injection of exogenous kininogens, along with trypomastigotes, supports the notion that generation of kinin "danger" signals is intensified through cooperative activation of TLR2 and B2R. In summary, we have described a s.c. infection model where type 1 immunity is vigorously up-regulated by bradykinin, an innate signal whose levels in peripheral tissues are controlled by an intricate interplay of TLR2, B2R, and ACE.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Plasma leakage through postcapillary venules is a common response to tissue injury inflicted by trauma, noxious stimuli, tumors, or pathogens. Upon diffusion of plasma proteins into peripheral tissues, multiple proteolytic cascades are activated, generating short-lived vasoactive and neurogenic peptides that amplify the initial inflammatory response. Whether mediated by plasma or tissue kallikrein, activation of the kinin system involves the proteolytic excision of bradykinin (BK)3 or lysyl-BK (LBK), respectively, from an internal moiety of their blood-borne precursors, high m.w. kininogens (HK) and low m.w. kininogens (1). Infections provide alternative opportunities for kinin generation by microbial proteases such as those secreted by bacteria (2, 3) or by parasitic protozoa such as Trypanosoma cruzi (4, 5, 6) and Leishmania donovani (7). Once released, the short-lived kinin peptides exert their pleiotropic effects by triggering G protein-coupled BK receptors (BRs) of the rhodopsin family (8, 9). Beyond their traditional role as proinflammatory mediators (10), kinins are now regarded as key modulators of vascular homeostasis (11). Of possible relevance to the understanding of immunoregulation, we recently reported that exogenous BK/LBK induce full-fledge maturation of dendritic cells (DCs) by activating BK B2 receptor (B2R) (12), a constitutively expressed receptor subtype that is also expressed in other cell types, such as pain-sensitive neurons and endothelial and smooth muscle cells (8).

The biological effects of kinins on B2R are limited through the degradation of their cognate ligands, BK/LBK, by peptidases such as angiotensin converting enzyme (ACE; kininase II; CD143) and neutral endopeptidase P (1, 13) and/or by desensitization and sequestration of B2R (8, 14). Inhibitors of ACE (ACEi) such as captopril and lisinopril prevent degradation of kinins thereby prolonging their half-life and enhancing their physiological effects (13). In contrast to B2R, B1R is the prototype of an inducible receptor present in low levels in normal tissues and highly up-regulated in injured or inflamed tissues (9). Generation of B1R agonists depends on enzymatic removal of the C-terminal Arg residue from intact kinins by carboxypeptidase M/N (kininase II) (9).

Immunological studies performed in models of Th2-dependent lung inflammation induced in BALB/c mice immunized with OVA revealed that exogenous kinins (BK/LBK) drive Th1 polarization via the IL-12 pathway (12). Of further interest, we found that in vivo administration of ACEi enhanced IL-12 production by DCs via B2R (12), suggesting that endogenous levels of kinin generated in "steady state" is likely dampened by the action of kinin-degrading peptidases expressed in peripheral and/or lymphoid tissues. The possibility that ACE may have a contributory role in the maintenance of immune homeostasis is further supported by a recent report showing that its expression is highly up-regulated in immature human DCs (15).

In the context of infection, little is known about the contribution of endogenous "danger" signals for DCs (16) such as kinins (12), ATP (17), heat shock proteins (18), uric acid (19) and endovanilloids (20). This analysis is complicated by the fact that pathogens are able to directly activate DCs by triggering pattern recognition receptors such as TLRs (21, 22). Furthermore, in some infections the microbial stimuli may initiate inflammation by triggering TLRs expressed by other innate sentinel-type of cells, such as macrophages and mast cells (23). In the present work, we addressed this issue in a mouse model of infection by T. cruzi, a parasitic protozoan that activates the kinin system through its major cysteine protease (cruzipain) (4, 5, 6, 24, 25) and displays potent microbial signatures for either TLR2 (26, 27, 28) or TLR4 (29). The contribution of TLR/MyD88-dependent mechanisms to innate resistance to T. cruzi infection was previously documented in mice infected by the i.p. route (30). Here, we used a different model., i.e., mice infected by the s.c. route, to characterize the differential roles of TLRs and BRs as drivers of inflammation and immunity. By studying the dynamics of microvascular inflammation evoked by this pathogen, we found evidence that the extent of kinins generated in infected paw tissues is governed by an intricate interplay of TLR2, B2R, and ACE. Perturbations in kinin homeostasis, here sought through the use of a single-dose of ACE inhibitors, vigorously up-regulate type 1 immune responses via the B2R-dependent innate pathway. In summary, we have described a s.c. infection of T. cruzi infection that may serve as a paradigm for studies of novel mechanisms linking innate to adaptive immunity.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Disclosures
 References
 
Mice and parasites

Experiments were done with mouse strains BALB/c, J129 WT (B2R+/+), J129 B2R–/–, C57BL/6 WT (TLR2+/+), C57BL/6 TLR2–/– (donated by Dr. S. Akira, Osaka University, Osaka, Japan), C3H/HePAS (TLR4+/+), C3H/HeJ (TLR4def, donated by Dr. M. Russo, Universidade de São Paulo, São Paulo, Brazil). Tissue culture trypomastigotes (TCTs) and epimastigotes of Dm28c clone of T. cruzi were cultivated in standard liver infusion tryptose medium containing 10% FCS (Invitrogen Life Technologies).

Isolation of parasite molecules

Cruzipain was isolated from epimastigotes using a procedure modified from Lima et al. (31). Briefly, suspensions of epimastigote pellets (40 g) were initially extracted in LPS-free distilled water (500 ml) containing 2 mM EDTA, 1 mM PMSF (Sigma-Aldrich), 1 µg/ml pepstatin (Sigma-Aldrich), at pH 5.2. After centrifugation at 13,500 x g (1 h at 4°C), the soluble extract was slowly acidified with HCl to pH 4.2 (2 h at 4°C). After clearing the aggregates by another cycle of centrifugation, we treated the cruzipain-rich acidic supernatant with ice-cold saturated ammonium sulfate (60% final concentration) under gentle stirring at 4°C. After washing the protein precipitates three times with ice-cold 60% saturated ammonium sulfate, the pellet was gently dissolved in 30 ml of ice-cold PBS-EDTA 2 mM (pH 7.2). Following extensive dialysis with the same buffer, aggregates were cleared by centrifugation and the soluble protein fraction (40 ml) was extracted with 80 ml of dehydrated n-butanol at 4°C. After carefully isolating the water-soluble fraction, the sample was dialyzed against PBS (pH 7.2) and then subjected to affinity chromatography on a thiol-Sepharose 4B (Pharmacia). Before applying the cruzipain-rich sample to the resin, we added 5 mM DTT for 15 min. After removing the excess of the reducing agent through a brief step of precipitation with 60% saturated ammonium sulfate, the precipitates were quickly dissolved in PBS, and then applied to the thiol-Sepharose 4B (Pharmacia) equilibrated in 100 mM Tris-HCl and 2 mM EDTA (pH 7.4). The bound protease was eluted from the resin with 20 mM DTT, added to the same buffer. After pooling the enzymatically active cruzipain fractions as described (31), the purified protease was dialyzed against PBS, concentrated by centrifugation in Centricon 10 filters. After checking for biochemical homogeneity, purified cruzipain was stored at –20°C. GPI-linked mucins (trypomastigote-derived GPI-anchored mucin (tGPI-m)) were purified from TCTs of the Y strain as described (32). Electrospray ionization-mass spectrometry (negative ion-mode) analysis did not show indication of LPS/lipid A contamination in the tGPI-m sample within the limits of detection of lipid A, estimated as 1–10 femtomoles. In addition, no contaminating Mycoplasma lipopeptides were found by positive ion-mode electrospray ionization-mass spectrometry and MALDI-TOF-MS analyses after digestion of tGPI-m with proteinase K, as described (26). LPS contamination of these preparations was ruled out using the Limulus amebocyte lysate assay (BioWhittaker).

Isolation and characterization of DC from mice infected with T. cruzi

BALB/c mice pretreated, or not, with 10 mg/kg i.p ACEi (captopril) (Sigma-Aldrich) and/or 100 µg/kg s.c. HOE-140 (Aventis), were injected 1 h later in the hind footpads with 5 x 105 TCTs. DCs were isolated from popliteal lymph nodes (LN) at 18 h postinfection (p.i.). Briefly, pooled LN fragments were treated with collagenase D (Sigma-Aldrich) and DCs were positively selected using magnetic beads covered with anti-mouse CD11c (90% pure; Miltenyi Biotec). CD11c+ DCs (1 x 106 cells/well) were incubated for 18 h, and 10 µg/ml brefeldin A (Sigma-Aldrich) was added for the last 4 h. To stain for intracellular IL-12 and cell surface CD11c, 1 x 106 DCs were washed and preincubated with 2% of normal mouse serum (NMS) supplemented with 1 µg of anti-mouse CD16/CD32 FC{gamma} III/IIR (BD Pharmingen). The washed cells were stained with anti-mouse CD11c-FITC (BD Pharmingen) diluted in PBS/2% NMS. After washing two times with PBS, the cells were fixed in 2% paraformaldehyde, washed, and permeabilized with 0.05% saponin. Staining with PE-labeled anti-IL-12 p40/p70 (BD Pharmingen) was done in PBS/2% NMS/0.05% saponin. Samples were analyzed by FACScan (BD Biosciences), and data analyses were done with CellQuest software (BD Biosciences) or Win-MDI software (The Scripps Research Institute). DCs were also cultivated for 24 h at 37°C and IL-12 p70 (R&D Systems) levels in culture supernatant were quantified by ELISA.

Kinin-mediated induction of cytokine production by T cells from infected mice

BALB/c mice pretreated, or not, with 10 mg/kg i.p ACEi (captopril) and/or 100 µg/kg s.c. HOE-140 were inoculated 1 h later with 1 x 106 TCTs (paw). Infection of J129 WT (B2R+/+), J129 B2R–/–, C3H/HePAS (TLR4+/+), C3H/HeJ (TLR4def), C57BL/6 WT (TLR2+/+) mouse strains was done by inoculating 5 x 105 TCTs, or alternatively with an equivalent dose of TCTs preincubated (20 min at room temperature) with 10 µM methylpiperazine-Phe-homoPhe-vinylsulfone-benzene (VSPh-TCT) per hind footpad (33). After 10 days, LN T cells were isolated and stimulated with 25 µg/ml soluble T. cruzi (epimastigote) Ag. Culture supernatants were collected after 48 h and levels of IFN-{gamma} were quantified by ELISA (R&D Systems).

Kininogen-dependent rescue of deficient type 1 immune responses in infected TLR2–/– mice

C57BL/6 TLR2–/– mice or TLR2+/+ (controls) pretreated with 10 mg/kg i.p. ACEi (captopril) and/or 100 µg/kg s.c. HOE-140 were infected 1 h later with a suspension of 5 x 105 TCTs (paw). In some experiments, the ACEi-TLR2–/– mice were injected with a TCT suspension contained 10 µg/ml BK (Sigma-Aldrich) or 50 µg/ml human HK (Calbiochem.), or alternatively, with VSPh-TCT suspension supplemented with 50 µg/ml HK. After 10 days, LN T cells were isolated and stimulated with 25 µg/ml soluble T. cruzi (epimastigote) Ag. Culture supernatants were collected after 48 h and IFN-{gamma} was quantified by ELISA (R&D Systems).

Edema assays

Animals pretreated with 10 mg/kg i.p. ACEi (captopril) and/or 100 µg/kg s.c. HOE-140 were injected 1 h later with 1 x 106 TCTs or equivalent numbers of epimastigotes, as previously reported (31). Where indicated, the mice were inoculated with VSPh-TCT. For polymorphonuclear neutrophil (PMN) depletion, mice were injected i.p. with 0.45 ml of a 1/10 dilution in PBS (34) of rabbit antiserum to PMN (Accurate Chemical) or an equivalent volume of normal rabbit serum (control). TLR2–/– and TLR4def mice, pretreated or not with ACEi and/or HOE-140 as described above, were injected with 10 nM purified tGPI-mucin alone or combined with 5 nM purified cruzipain. When indicated, cruzipain was previously inactivated by 5 nM L-trans-epoxysuccinyl-leucylamido-(4-guanidino)butane (E-64). Edema volumes reflecting the difference between injected and contralateral paws were measured by plethysmometer (24).

Intravital microscopy in the hamster cheek pouch

To study vascular permeability increases in postcapillary venules of the hamster cheek pouch model, fluorescein-labeled dextran (FITC-dextran, molecular mass ~150,000 Da; 250 mg/kg body weight) were injected i.v. in the pouch tissues superfused with HEPES/bicarbonate-buffered saline solution at a constant rate of 6 ml/min at 35°C, before topical application of parasites, as previously described (7). In some experiments, 1 µM ACEi (captopril) was added to the superfusing medium. The perfusion flow was stopped for 10 min to allow for topical application of TCTs (2.5 x 107) in the cheek pouch. The number of "leaky spots" was counted at various time points after parasite challenge. Where required, the ACEi-treated cheek pouch received 0.5 µM HOE-140, before parasite application topically. To study the involvement of kininogens in the permeability-inducing activity of cruzipain, we first established baseline activity levels by applying increasing concentrations of activated cruzipain (range of 0.1–2.5 µM) to the ACEi-treated cheek pouch. No significant leakage was observed at cruzipain concentrations <0.25 µM. The experiments involved six consecutive topical applications of the test samples in the same cheek pouch tissues. This was performed with 30-min intervals between the tests, to permit tissue superfusion with ACEi medium. After testing the effect of activated cruzipain (0.25 µM) alone, the cheek pouch was superfused with ACEi medium for 30 min. This was followed by topically applied HK (500 nM), added immediately before activated cruzipain. After another 30 min of tissue superfusion with ACEi medium, we added HK alone, i.e., without the protease. The fourth test involved HK application followed by addition of cruzipain inactivated by E-64. In the fifth test, we checked whether the microvascular bed was still responsive to the combination of HK and activated cruzipain. Finally, ACEi-treated cheek pouch tissues were pretreated with HOE-140, before a final application of cruzipain/HK. Leaks induced by cruzipain were counted at 2, 5, 10, 15, 20, and 30 min. Peak activity responses resulting from the combined addition of HK and cruzipain were consistently observed at 5 min. For each test condition, average number of leaky sites was determined by collecting data from at least five hamsters.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Disclosures
 References
 
Kinins released in paw tissues infected by T. cruzi stimulate DC maturation via B2R

In a previous study (31), we reported that mice pretreated with a single-dose of captopril, an ACEi, develop a vigorous paw edema 3 h after inoculation of TCTs. The swelling reaction evoked by TCTs was intense in J129 B2R+/+ mice, but the parasites did not induce a significant vascular reaction in ACEi-treated J129 B2R–/– mice or in ACEi-J129 B2R+/+ mice pretreated with the selective B2R antagonist HOE-140 (31). Here, we used the same s.c. model of T. cruzi infection to test the proposition that endogenously released kinins link innate to adaptive immunity (12). To this end, we inoculated TCTs in the paw of BALB/c mice and isolated CD11c+ DCs from popliteal LN, 18 h p.i. Analysis of IL-12 production by FACS showed that the percentage of CD11c+ DCs expressing high levels of IL-12 was drastically increased in mice pretreated with ACEi, but this effect was nullified by HOE-140 (Fig. 1A). By contrast, CD11c+ DCs isolated from mice infected in the absence of ACEi displayed low IL-12 responses, indicating that the innate effects of released kinins is normally blunted by this major kinin-degrading peptidase. As an additional control, CD11c+ DCs isolated from noninfected mice pretreated with ACEi did not produce IL-12 (Fig. 1A). Essentially the same profile was obtained when we used ELISA to quantify IL-12p70 produced by CD11c+ DCs under these conditions (Fig. 1B). Collectively, our results indicate that kinins generated in the infected paw can overtly stimulate IL-12 production by CD11c+ DCs via the B2R-signaling pathway.


Figure 1
View larger version (10K):
[in this window]
[in a new window]
  		FIGURE 1. IL-12 production by DCs isolated from draining LN of infected mice is B2R dependent. BALB/c male mice were pretreated ({blacksquare}) or not ({square}) with a single-dose of 10 mg/kg (i.p.) captopril (ACEi). Where indicated, the mice were pretreated with 100 µg/kg HOE-140. One hour later, these animals were injected with 1 x 106 TCTs in the paw. CD11c+ DCs were isolated from popliteal LN at 18 h p.i. and cultured in complete RPMI 1640 medium. Noninfected ACEi-BALB/c served as control. A, Intracellular IL-12 produced by CD11c+ DCs. FACS profiles were done with anti-CD11c-FITC and anti-IL12-PE. Each bar represents the percentage of DCs producing IL-12 beyond threshold levels. B, ELISA quantification of IL-12 p70 in DC supernatants obtained under above conditions. Data represent means ± SD from four independent experiments (n = 10 mice/group).

 
Kinins link innate to adaptive immunity in T. cruzi-infected mice via the B2R pathway

Because the intensity of IL-12 production by DCs in vivo correlates with extent of kinin generation in primary sites of infection, we then checked whether these innate modulatory effects translate into changes of adaptive immunity. Recall responses by LN T cells isolated from BALB/c mice 10 days after infection showed that ACEi-BALB/c produced over 4-fold more IFN-{gamma} than mice infected in absence of the ACEi (Fig. 2A). In the absence of T. cruzi Ag, the LN T cells only secreted baseline levels of IFN-{gamma} (data not shown). We then checked whether blockade of B2R activation at the onset of infection could prevent ACEi-dependent up-regulation of type 1 responses. Indeed, T cells derived from ACEi-BALB/c mice pretreated with HOE-140 produced low levels of IFN-{gamma} upon in vitro stimulation with T. cruzi Ag (Fig. 2A). IL-4 was not detected in mice pretreated with the B2R antagonist, irrespective of ACEi administration (data not shown). To further assess the immunoregulatory role of kinins, we then compared the impact of ACEi treatment in adaptive responses of wild-type (WT) (B2R+/+) J129 mice vs J129 B2R–/–. Similar to BALB/c mice, T cells isolated from draining LN of ACEi-treated B2R+/+ mice vigorously up-regulated IFN-{gamma} production upon stimulation with T. cruzi Ag in vitro, whereas T cells derived from HOE-140-treated B2R+/+ mice only produced baseline levels of IFN-{gamma} (Fig. 2B). Cultures run in the absence of T. cruzi Ag only showed baseline levels of IFN-{gamma} (data not shown). In contrast, recall assays performed with T cells isolated from infected ACEi-B2R–/– mice showed that IFN-{gamma} production was not up-regulated (Fig. 2B). Collectively, these results support the proposition that ACEi promotes increased generation of innate kinin signals in the primary sites of infection, thereby stimulating adaptive immunity via the B2R/IL-12 pathway.


Figure 2
View larger version (11K):
[in this window]
[in a new window]
  		FIGURE 2. Kinins link innate to adaptive immune responses. A, ELISA determination of IFN-{gamma} production by popliteal LN T cells isolated from infected BALB/c male mice, following in vitro stimulation with soluble T. cruzi (epimastigote) Ag. The mice were pretreated (i.p.) with ACEi ({blacksquare}) or not ({square}), 1 h before paw injection of 1 x 106 TCTs. Where indicated, the mice were pretreated (s.c.) with HOE-140. The data are representative of three independent experiments, with similar results. B, Ag-specific IFN-{gamma} production by popliteal LN T cells isolated from infected B2R+/+ and B2R–/– mice (n = 4 each) pretreated with ACEi ({blacksquare}) or not ({square}). Where indicated, the mice were pretreated 1 h before infection with HOE-140. Results are representative of two independent experiments with similar results. Statistical differences between mean values were evaluated by ANOVA, and pair-wise comparisons (represented by a and b) were done by the Tukey test (*, p < 0.01). {blacksquare}, Mice pretreated with ACEi; {square}, mice pretreated with PBS.

 
Generation of immunoregulatory kinins depends on cooperation of TLR2 and B2R

Considering that host resistance in mice infected with T. cruzi by the i.p. route depends on pathogen recognition by TLRs (24), we asked whether generation of immunoregulatory kinins in infected paw tissues might be subordinated to parasite-induced activation of TLR4 and/or TLR2 (25, 26, 27, 28, 29). As internal controls, separate groups of mice were injected with TCTs pretreated with VSPh, a potent irreversible inhibitor of the kinin-releasing cysteine protease, cruzipain (33). First, we tested whether interference with kinin homeostasis in TLR4+/+ (C3H/HePAS) and TLR4def (C3H/HeJ) mice resulted in modulation of IFN-{gamma} production by Ag-specific T cells. ELISA data showed that the recall responses of both mice strains were significant, albeit of low intensity, when the TLR4+/+ or TLR4def mice were infected by TCTs in the absence of ACEi pretreatment. In contrast, LN-borne T cells from infected ACEi-TLR4+/+ or ACEi-TLR4def mice showed largely congruent patterns, i.e., Ag-specific IFN-{gamma} production was strongly up-regulated in both strains, and HOE-140 completely abrogated these effects (Fig. 3A). Of note, T cells from ACEi-TLR4+/+ or ACEi-TLR4def mice inoculated with TCT-VSPh failed to up-regulate IFN-{gamma} production (Fig. 3A), supporting the notion that the parasites generate kinins through the proteolytic activity of cruzipain. Thus, our results suggest that ACEi up-regulates type 1 immune responses by increasing the half-life of the innate kinin signals which cruzipain generates in the infected paw, without requirement for TLR4 signaling. We then compared the Ag-specific T cell responses of TLR2+/+ and TLR2–/– mice infected with TCTs. As in the previous set of experiments, in the absence of ACEi-pretreatment, the experienced T cells from both TLR2+/+ and TLR2–/– mice produced significant, albeit relatively low, IFN-{gamma} upon Ag stimulation in vitro (Fig. 3B). However, drastic differences were observed when we compared the recall responses of LN-borne T cells from ACEi-TLR2+/+ and ACEi-TLR2–/– mice infected by TCTs: in contrast to the strongly up-regulated IFN-{gamma} production observed in ACEi-treated TLR2+/+ mice, the production of the type 1 cytokine was reduced in ACEi-TLR2–/– (Fig. 3B). Notably, the reduced IFN-{gamma} response of T cells from ACEi-TLR2–/– mice was not due to an intrinsic defect in the B2R signaling cascade because the production of the type 1 cytokine was rescued by inoculating the trypomastigotes in suspensions containing exogenous bradykinin, while HOE-140 canceled these effects (Fig. 3B). These internal controls indicate that B2R signaling induced by provision of exogenous bradykinin to infection sites has compensated for the deficient adaptive response of TLR2–/– mice. Similar to data obtained with TLR4+/+, the injection of TCT-VSPh failed to up-regulate the type 1 response in ACEi-TLR2+/+ mice, thus further suggesting that generation of the innate kinin signal in peripheral tissues is dependent on cruzipain activity (Fig. 3B). Collectively, these data suggest that type 1 immune responses depend on cooperative activation of TLR2 and B2R, by mechanisms involving an intricate interplay of cruzipain and ACE at early stages of infection.


Figure 3
View larger version (11K):
[in this window]
[in a new window]
  		FIGURE 3. Type 1 instructive function of kinins is impaired in infected TLR2–/– mice. A, ELISA determinations of IFN-{gamma} produced by LN T cells isolated (10 days p.i.) from infected TLR4+/+ or TLR4def mice. The mice were pretreated (i.p.) with ACEi ({blacksquare}) or not ({square}), 1 h before paw injection of 106 TCTs, or equivalent inoculums of VSPh-treated TCTs. Where indicated, the mice were also pretreated (s.c.) with HOE-140. In vitro recall responses were obtained by incubating LN T cells with soluble T. cruzi Ag. Data represent means ± SD of IFN-{gamma} levels in supernatants, obtained by pooling cells (n = 3 mice/group). Results are representative of two independent experiment with similar results. B, In vitro recall responses of T cells from TLR2+/+ or TLR2–/– inoculated either with 106 of TCTs or VSPh-TCTs. Where indicated, the mice were inoculated with TCTs along with 10 nM BK. Data (means ± SD) represent IFN-{gamma} levels in culture supernatants, obtained by pooling cells (n = 4 mice/group). Results are representative of two independent experiments with similar results. Statistical differences between mean values were evaluated by ANOVA, and pair-wise comparisons were done by the Tukey test. Statistical significance is indicated by asterisks (*, p < 0.05).

 
TLR2 is required for overt activation of the kinin system by TCTs

After showing that induction of type 1 immune responses depends on cooperative activation of TLR2 and B2R, we asked whether the parasite’s ability to activate the kinin system was dependent on TLR recognition of the pathogen. We first addressed this question by measuring the intensity of parasite-evoked paw swelling (kinin/B2R dependent) in mice displaying functional deficiency of TLR2 or TLR4. First, we compared the intensity of trypomastigote-evoked edema in ACEi-TLR4 WT mice (TLR4+/+, C3H/HePAS) vs TLR4-deficient mutant mice (TLR4def, C3H/HeJ). In both strains, trypomastigotes elicited weak but significant edema in the absence of ACEi (Fig. 4A) and the vascular reaction was drastically enhanced upon pretreatment with ACEi. Intriguingly, HOE-140 almost completely abolished the inflammation in ACEi-treated TLR4def, while partially reducing the anti-inflammatory effect in ACEi-treated TLR4+/+ mice (Fig. 4A). These results observed in TLR4def mice suggest that this strain may compensate TLR4 deficiency by dominantly engaging B2R-dependent pathways of inflammation. We then compared the magnitude of swelling in ACEi-treated WT TLR2+/+ vs TLR2–/– mice inoculated with TCTs (Fig. 4B). Paw swelling was markedly reduced in ACEi-TLR2–/– mice as compared with ACEi-TLR2+/+. This differential effect is not due to an impaired B2R function in the TLR2–/– mice because injection of synthetic bradykinin induced a prominent edema in such animals (Fig. 4B). Thus, our results suggest that parasite engagement of TLR2, but not TLR4, is mandatory for overt activation of the kinin pathway in the s.c. model of T. cruzi infection.


Figure 4
View larger version (10K):
[in this window]
[in a new window]
  		FIGURE 4. TCTs evoke inflammation by stimulating cooperative activation of TLR2 and B2R. A, Paw edema (3 h) induced by injection of 1 x 106 TCTs in the paw of TLR4+/+ and TLR4def mice. The mice were pretreated with ACEi ({blacksquare}), or not ({square}), 1 h before parasite injection. Where indicated, the mice were also pretreated with HOE-140. B, Edema (3 h) induced by injection of TCTs (106) or 10 nM BK in ACEi-TLR2+/+ or ACEi-TLR2–/– mice. The results (means ± SD) are representative of three independent experiments (n = 5). Statistical differences between mean values were evaluated by ANOVA, and pair-wise comparisons (represented by a and b) were done by the Tukey test (*, p < 0.01).

 
Leakage of plasma supplies kininogens to infected peripheral tissues, thus allowing for cruzipain-mediated generation of kinins

To investigate the mechanisms underlying plasma leakage evoked by trypomastigotes, we studied the dynamics of inflammation induced by topical application of the pathogen in the microvascular beds of the hamster cheek pouch. Addition of TCTs provoked significant leakage of FITC-dextran in ACEi-treated cheek pouch within 2–3 min of application (Fig. 5A), coinciding with early signs of PMN adherence to the endothelium (our unpublished observation). The microvascular permeability response induced by TCTs peaked at 15 min p.i., fading thereafter and reaching basal levels within 30–40 min. Similar to the B2R-driven edema responses which TCTs induced in ACEi-mice (Fig. 4), the vascular permeability responses in the ACEi-treated cheek pouch were canceled by HOE-140 (Fig. 5A). In addition, topically applied VSPh-TCTs only elicited weak microvascular leakage responses, suggesting that the parasite’s proedematogenic activity depends on generation of kinins by cruzipain (data not shown). To further investigate this possibility, we verified whether topical application of activated cruzipain could directly promote microvascular leakage in the ACEi-treated cheek pouch. Our results showed that activated cruzipain evoked minor vascular permeability increases (Fig. 5B). We thus reasoned that, in the "steady state," the pouch extravascular tissues might not contain sufficient levels of endogenous kininogens, thus precluding release of significant levels of kinins by cruzipain. Indeed, by exogenously applying purified HK along with activated cruzipain into the ACEi-treated cheek pouch we could record a massive increase in vascular permeability (Fig. 5B). Controls performed by consecutive applications of HK, either alone or combined with E-64-inactivated cruzipain, caused negligible vascular permeability responses in the same ACEi-treated pouch (Fig. 5B). To make sure that tissues were not exhausted at the end of these consecutive applications, the pouch was rechallenged with activated cruzipain and HK. Significant responses were again observed, and furthermore, HOE-140 blocked these effects (Fig. 5B). Together, these in vivo studies suggest that availability of plasma-borne kininogens in peripheral tissues is a prerequisite for release of kinins by cruzipain. To further investigate the proinflammatory role of cruzipain, we turned to the mouse model to compare the edematogenic responses of TCTs vs VSPh-TCT. As previously reported (24), our positive controls (Fig. 6A) showed that TCTs injected s.c. in ACEi-treated C57BL/6 mice induced a powerful paw swelling that was canceled by HOE-140. In contrast, VSPh-TCTs were unable to evoke a significant edema in ACEi-treated mice, supporting the notion that cruzipain enzyme activity is necessary for kinin generation in vivo. Next, we injected epimastigotes in the paw of ACEi mice and noted that these noninfective forms of T. cruzi failed to induce significant paw edema, irrespective of ACEi pretreatment (Fig. 6A). At first sight, this result seemed to be contradictory because epimastigotes express high levels of cruzipain (35). To further evaluate this issue, we injected purified cruzipain into ACEi-treated mice and found that, similar to cheek pouch assays, the protease did not induce significant paw swelling (Fig. 6A). Because epimastigotes or cruzipain per se are unable to activate the kinin system in vivo, we reasoned that TCTs might depend on developmentally regulated proinflammatory cofactor(s), i.e., absent in epimastigotes, to drive leakage of plasma-borne kininogens (cruzipain substrate) into peripheral tissues. Because TCTs failed to induce B2R-dependent edema in ACEi-TLR2–/– mice (Fig. 4B), we inferred that activation of the kinin system might depend on the cooperative activities of TLR2 ligand(s) and cruzipain.


Figure 5
View larger version (12K):
[in this window]
[in a new window]
  		FIGURE 5. Availability of kininogens in extravascular tissues is a limiting step controlling cruzipain-mediated generation of vasoactive kinins. A, Determination of mean number of FITC-dextran venular leaks evoked by multiple injections (numbers are given in brackets) of 1 x 106 TCTs, with 30-min intervals each, in the hamster cheek pouch tissues superfused with HEPES buffer. ACEi (1 µM captopril) was applied for 5 min, in the presence or absence of HOE-140 (0.5 µM), before application of TCTs. The cheek pouch tissues are washed, after being exposed to the parasites. BK was added (250 nM) at 60 min as internal control (see arrow). B, Mean number of leaks in postcapillary venules of ACEi-treated cheek pouch induced by consecutive (topical) application of: 1) 0.25 µM of purified cruzipain (CZP) preactivated with DTT, 2) activated CZP and 500 nM of purified human HK, 3) HK alone, 4) HK combined to CZP inactivated by the cysteine protease inhibitor E-64 (0.25 µM), 5) a final rechallenge with activated CZP combined with HK, 6) activated CZP and HK applied to vascular beds pretreated with HOE-140 (0.5 µM). Data represent means ± SD of at least five independent experiments per point (n = 5).

 

Figure 6
View larger version (10K):
[in this window]
[in a new window]
  		FIGURE 6. Cooperative action of tGPI-m and cruzipain drives TLR2/B2R "cross-talk." A, Paw edema (3 h) in mice induced by injection of either 1 x 106 TCTs, TCTs pretreated with the cruzipain inhibitor VSPh (VSPh-TCT), epimastigotes (EPI), or 5 nM of activated cruzipain (CZP). The mice were pretreated with ACEi ({blacksquare}), or not ({square}), 1 h before injection with parasites or CZP. Where indicated, the mice were pretreated with HOE-140. B, Edema in TLR4def mice, pretreated or not with ACEi and/or HOE140 1 h before paw injection of either activated cruzipain (CZP), tGPI-m (10 nM) combined to cruzipain (5 nM) or tGPI-m combined to E64-treated cruzipain. C, Edema induced by tGPI-m/cruzipain in ACEi-TLR2+/+ or ACEi-TLR2–/– mice. The results (means ± SD) are representative of three independent experiments (n = 4). Statistical differences between mean values were evaluated by ANOVA, and pair-wise comparisons (represented by A and B) were done by the Tukey test (*, p < 0.01).

 
TLR2-B2R "cross-talk" is driven by the cooperative action of tGPI-m and cruzipain

Considering that tGPI-m is a TLR2 microbial signature expressed by tissue-culture trypomastigotes, but not by epimastigotes (26, 27, 28), we wondered whether the combined injection of tGPI-m and activated cruzipain may induce swelling, thus recapitulating the proinflammatory effects of TCTs. We used TLR4def mice to exclude the possibility that traces of endotoxin eventually contaminating cruzipain could possibly interfere with our assay system. Control experiments run in the absence of ACEi showed that combined injection of tGPI-m and cruzipain produced only a minor edema in TLR4def mice (Fig. 6B). However, a striking swelling was observed when we injected tGPI-m and cruzipain in ACEi-treated mice, while injection of tGPI-m or cruzipain alone had minor effects (Fig. 6B). Notably, the vigorous synergistic responses elicited by tGPI-m/cruzipain were canceled when ACEi-TLR4def mice were pretreated with HOE-140 or when cruzipain was previously inactivated by the irreversible inhibitor E-64 (Fig. 6B). Notably, the potent edema that tGPI-m/cruzipain induced in ACEi-treated TLR2+/+ mice was markedly attenuated in TLR2–/– mice (Fig. 6C).

TLR2 and neutrophils are required for overt activation of the kinin system

Awareness that tGPI-m drives neutrophil recruitment via TLR2 (36) led us to examine whether kinin system activation was subordinated to TLR2-mediated activation of PMNs. We investigated this possibility by treating TLR2+/+ mice with specific anti-PMN Abs before inoculation of trypomastigotes. After 18 h, a single dose of ACEi was applied to the PMN-depleted mice, and the animals were subsequently challenged with TCTs. Infected animals pretreated with nonimmune serum developed an appreciable paw edema (13 ± 1 µl; n = 5; data representative of three independent assays) while PMN-depleted mice displayed negligible responses under these conditions (< 1 µl; n = 5). Consistent with these data, injection of tGPI-m/cruzipain failed to induce swelling in PMN-depleted BALB/c mice irrespective of presence of ACEi (our unpublished observation). Combined, these results suggest that tGPI-m and cruzipain may promote plasma leakage by activating PMN through mechanisms that may involve a long-distance "cross-talk" between TLR2 and B2R.

TLR2-driven kininogen influx into peripheral tissues is the limiting step for B2R-dependent up-regulation of adaptive immunity

Earlier in this work, we showed evidences that ACEi-treated TLR2–/– mice failed to up-regulate type 1 immune responses in response to TCTs (Fig. 3B). Internal controls showed that TLR2–/– mice do not have any intrinsic defect in B2R signaling because injection of exogenous BK along with TCTs restored the deficient type 1 immune responses of infected TLR2–/– mice (Fig. 3B). Because TCTs evoked a mild edema in the paw of ACEi-TLR2–/– mice (Fig. 4B), we reasoned that reduced influx of plasma-borne kininogens into the peripheral tissues probably accounted for the deficient phenotypes. To test this hypothesis, we sought to "bypass" the requirement for TLR2-dependent plasma leakage by injecting TCTs into ACEi-TLR2–/– mice along with exogenous HK. Our results showed that administration of exogenous HK to TCT suspension led to a drastic increase in IFN-{gamma} levels produced by T cells from ACEi-TLR2–/– at day 10 p.i. (Fig. 7). Of note, HOE-140 abrogated the HK-dependent rescuing of adaptive immunity, indicating that this process ultimately led to the activation of B2R. Next, we monitored whether the effects of exogenous HK indeed depend on proteolytic processing by cruzipain. This was tested by injecting VSPh-TCTs combined to the purified HK into ACEi-TLR2–/– mice. Assessment of Ag-specific responses (Fig. 7) showed that LN T cells from mice infected with VSPh-TCT produced significantly lower levels of IFN-{gamma} as compared with mice injected with TCTs and HK. Collectively, these results indicated that the deficient link between innate and adaptive immunity observed in ACEi-TLR2–/– mice is restored by kinins liberated from the exogenously supplied kininogen through the activity of cruzipain. Thus, it appears that TCTs must activate TLR2/PMNs to drive the influx of blood-borne kininogens into the site of infection, thereby allowing for peripheral generation of kinins through the proteolytic activity of cruzipain (Fig. 8). Further downstream, the short-lived kinins act as maturation signals for DCs (12), thus linking innate to adaptive immunity.


Figure 7
View larger version (10K):
[in this window]
[in a new window]
  		FIGURE 7. Exogenous kininogen rescues type 1 cytokine production in TLR2–/– mice. Recall responses of LN T cells isolated from ACEi-TLR2–/– mice (n = 4/group) injected 10 days earlier with suspensions of TCTs (1 x 106), or with the same inoculums of VSPh-TCTs, in the presence or absence of exogenous HK (50 µg/ml). Where indicated, the ACEi mice were pretreated with HOE-140 (s.c). T cells isolated from draining LN (10 days p.i.) were stimulated in vitro with 25 µg/ml soluble T. cruzi Ag, and the IFN-{gamma} levels in culture supernatants were quantified by ELISA. ACEi-TLR2+/+ mice were used as positive controls. One control group consisting of noninfected ACEi mice was injected with HK alone. Results represent means ± SD of two independent experiments obtained by pooling cells from four mice per group. Statistics were done by ANOVA and pair-wise comparisons were done by the Tukey test (*, p < 0.01).

 

Figure 8
View larger version (16K):
[in this window]
[in a new window]
  		FIGURE 8. Schematic model depicting the dynamics of parasite-evoked inflammation Left, Trypomastigotes shed developmentally regulated PAMPs such as tGPI-m. These PAMPs are recognized by TLR2 expressed by interstitial cells such as macrophages or mast cells (1). Activation of these sentinel cells leads to secretion of inflammatory mediators such as TNF-{alpha} and chemokines (2). Circulating PMNs adhere to the activated endothelium. Due to plasma extravasation, plasma-borne kininogens rapidly accumulate in peripheral tissues (3). Center, Acting further downstream, the parasite cysteine protease cruzipain (CZP) processes kininogens, liberating vasoactive kinins (BK) (4). Right, The short-lived kinins activate B2R of endothelial cells, thus augmenting plasma extravasation (5). As inflammation escalates, the levels of endogenous kinins that are generated in the interstitial tissues is further raised, owing to cruzipain-mediated processing of kininogens. Acting as alert signals, the short-lived kinins induce full-fledge maturation of CD11c+ DCs via the B2R signaling pathway (6). The innate effects of BK are counterbalanced by the kinin-degrading activity of ACE (7). Inhibitors of ACE (ACEi) such as captopril up-regulate type 1 immune responses because kinin degradation is attenuated, thus augmenting the half-life of such potent "danger" signals in peripheral infection sites (8).

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Disclosures
 References
 
Our studies add substance to the understanding of molecular mechanisms underlying innate recognition of protozoan parasites. The s.c. infection model presented herein proposes the cooperation of TLR2 and B2R as signaling effectors of immunity. Our mechanistic studies revealed that TLR2 activation by microbial signatures present in tissue culture trypomastigotes promote diffusion of plasma-borne kininogens to the sites of infection, allowing for cruzipain-mediated liberation of kinin "danger" signals in peripheral tissues. Acting further downstream, endogenously released kinins stimulate IL-12 production by LN CD11c+ DCs via the B2R-signaling pathway, and mount a full-fledged type 1 adaptive response.

The evidence for an intertwined role of TLR2 and B2R as positive modulators of type 1 immunity in the s.c. model of infection contrasts with the relatively marginal role which TLR2 plays as an effector of innate immunity in mice infected by i.p. route (30). Of further interest, we recently found that B2R–/– mice infected by the i.p. route exhibit a highly susceptible phenotype (our unpublished observation). In this context, it has been recently documented that MyD88–/– mice infected with T. cruzi via i.p. also display heightened susceptibility to T. cruzi infection (30). Pertinently, it was shown that IFN-{gamma}–/– mice infected by the i.p. route displayed a more accentuated parasitemia and mortality than MyD88–/– mice, suggesting that IL-12 and IFN-{gamma} production is, at least to some extent, controlled by MyD88-independent pathway(s) (30). Additional work is required to determine the relative role of MyD88-dependent (37) and B2R-dependent pathways in murine resistance to experimental Chagas’ disease.

The finding that trypomastigotes evoked a weak edema in ACEi-TLR2–/– mice, along with evidence that these animals failed to up-regulate type 1 immunity, suggested that TLR2 triggering by the pathogen is critically required for full-fledge activation of the kinin system. Clues to understand the role of TLR2 in kinin system activation came from comparative analysis of the edematogenic responses induced by different developmental forms of T. cruzi. Unlike the potent responses induced by tissue-culture trypomastigotes, epimastigotes failed to evoke significant edema via the kinin/B2R pathway despite the fact that this avirulent form expresses high levels of the kinin-releasing protease cruzipain. Our search for putative T. cruzi pathogen-associated molecular patterns (PAMPs) (26, 27, 28, 29, 30) converged at the developmentally regulated tGPI-m because their unsaturated lipid moieties were previously characterized as potent TLR2 stimulators, being conspicuously expressed by tissue-culture derived trypomastigotes while absent in epimastigotes (27). Indeed, epimastigotes failed to up-regulate type 1 immune responses in TLR2+/+, irrespective of ACEi administration (data not shown), despite the high levels of cruzipain expressed by this parasite form. Considering that tGPI-m activate IFN-{gamma}-primed macrophages via TLR2 (26) and stimulate PMN extravasation in a TLR2-dependent manner (36), we therefore reasoned that activation of TLR2/PMN at the onset of infection may promote the influx of plasma-borne kininogens into peripheral tissues, allowing for cruzipain-dependent release of kinins from the interstitial kininogens (Fig. 8). In line with this notion, the proinflammatory phenotype of the tissue culture trypomastigotes was recapitulated by injecting purified tGPI-m along with activated cruzipain in WT but not in TLR2–/– mice. Although we do not claim here that tGPI-m is the only PAMP driving TLR2 activation by T. cruzi in vivo (25, 28), our data suggest that tGPI-m and cruzipain may act cooperatively, steering the activation of the kinin system via the TLR2-B2R axis.

The critical involvement of neutrophils in the TLR2-B2R axis is supported by data showing that paw edema induced either by TCTs was nullified in PMN-depleted mice. These results were consistent with intravascular microscopy observations in the hamster cheek pouch model indicating that leukocytes adhere to the endothelium within 1 min of trypomastigote application to the microvascular bed. Increased microvascular leakage was observed shortly thereafter, suggesting that resident sentinel cells (e.g., macrophages and/or mast cells) perhaps secreting TNF-{alpha} and/or chemokines (36) may promote endothelial/leukocyte adherence and drive plasma extravasation via CAP37/azurocidin (38). Thus, by controlling the influx of plasma-borne kininogens into peripheral tissues, TLR2/PMN may link the initial inflammatory responses elicited by the pathogen to subsequent kinin system activation, achieved through proteolytic release of kinins from interstitial kininogens, possibly through cruzipain (Fig. 8). In animals pretreated with ACEi, vasoactive kinins accumulate and thus intensify plasma extravasation through B2R activation (14). In addition, production of reactive oxygen species via NAD(P)H oxidase (39) may up-regulate endothelial expression of TLR2. These conditions, if met, may sustain inflammation by promoting a transcellular "cross-talk" between B2R and TLR2, similarly to mechanisms recently described for TLR4 and TLR2 (39).

The findings that ACEi-treated TLR2–/– mice fail to up-regulate type 1 immunity raised the possibility that DCs from this mouse strain "sense" TCTs via TLR2-independent pathways. Alternatively, the deficient phenotype of infected TLR2–/– may solely reflect impaired generation of kinin "danger" signals in peripheral tissues of such mice. Evidence in favor of the latter possibility was obtained upon injection of exogenous HK, along with trypomastigotes, in the paw of ACEi-treated TLR2–/– mice. This bypass maneuver rescued the defective type 1 immune response, suggesting that TLR2/PMN controls a limiting step governing the kinin-generation mechanism, i.e., the efflux of plasma-borne kininogens into peripheral sites of infection.

Previously, we have reported that exogenous kinins induce DC maturation through stimulation of their B2R, and proposed that kinins may function as endogenous "danger" signals that induce Th1 polarization via the IL-12 pathway (12). Here, we validated these premises by interfering with kinin homeostasis through the administration of a single-dose of ACEi shortly before onset of s.c. T. cruzi infection. Our results show that IL-12 production by CD11c+ DCs is vigorously induced in a kinin/B2R-dependent manner. This effect may reflect ACEi-dependent inhibition of the kinin-degrading activity of ACE (CD143) displayed by immature DCs (15), rendering these APCs hyperresponsive to kinin maturation signals (12). Alternatively, ACEi may potentiate neurogenic inflammation by intensifying activation of pain-sensitive fibers through kinin/B2R and vanilloid receptor signaling pathways (40), as this would indirectly provide "danger" signals for the innate immune system (20).

In conclusion, our analysis of the molecular mechanisms responsible for the endogenous generation of kinins in sites of infection appointed an intricate interplay of TLR2, B2R, and ACE, here characterized as modulators of antiparasite immunity.


   Acknowledgments
 
We thank J. H. McKerrow for donation of VSPh, B. Bergman and V. Calich for control Abs, S. Akira for TLR2–/– mice through M. Bellio, M. Russo for TLR4def mice. We acknowledge Alessandra Granato, Camilla Figueiredo de Castro for help with the mice infection experiments, and Leila Faustino and Alda F. Alves for technical assistance.


   Disclosures
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
References
 
The authors have no financial conflict of interest.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was funded by World Health Organization-Special Program for Research and Training in Tropical Diseases (IDA10340), Wellcome Trust (072349/Z/03/Z), Conselho Nacional de Pesquisas, Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro, Comissao de Aperfeiçoamento de Pessoal de Nival Superior, Fundaçao de Amparo à Pesquisa do Estado de Minas Gerais, and Fundaçao de Amparo à Pesquisa do Estado de Sao Paulo, Volkswagen Stiftung and Fonds der Chemischen Industrie. I.C.A. was supported by a National Institutes of Health Grant (5G12RR008124) to Border Biomedical Research Center/Biology/University of Texas El Paso. A.C.M. received a fellowship from the Tuberculosis Research Network/Conselho Nacional de Pesquisus. Back

2 Address correspondence and reprint requests to Dr. Julio Scharfstein, Universidade Federal do Rio de Janeiro, Centro de Ciências da Saúde, Instituto de Biofisica Carlos Chagas Filho, Laboratório de Imunologia Molecular, Bloco D. Sala D 007, Rio de Janeiro, Brazil. E-mail address: scharf{at}biof.ufrj.br Back

3 Abbreviations used in this paper: BK, bradykinin; HK, high m.w. kininogen; BR, BK receptor; DC, dendritic cell; ACE, angiotensin converting enzyme; ACEi, ACE inhibitor; TCT, tissue culture trypomastigote; LN, lymph node; NMS, normal mouse serum; tGPI-m, trypomastigote-derived GPI-anchored mucin; VSPh, methylpiperazine-Phe-homoPhe-vinylsulfone-benzene; PMN, polymorphonuclear neutrophil; WT, wild type; PAMP, pathogen-associated molecular pattern; LBK, lysyl-BK. Back

Received for publication February 27, 2006. Accepted for publication July 24, 2006.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 

  1. Bhoola, K. D., C. D. Figueroa, K. Worthy. 1992. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol. Rev. 44: 1-80. [Medline]
  2. Herwald, H., M. Collin, W. Müller-Esterl, L. Björck. 1996. Streptococcal cysteine proteinase releases kinins: a virulence mechanism. J. Exp. Med. 184: 665-673. [Abstract/Free Full Text]
  3. Imamura, T., S. Tanase, G. Szmyd, A. Kozik, J. Travis, J. Potempa. 2005. Induction of vascular leakage through release of bradykinin and a novel kinin by cysteine proteinases from Staphylococcus aureus. J. Exp. Med. 201: 1669-1676. [Abstract/Free Full Text]
  4. Del Nery, E., M. A. Juliano, A. P. Lima, J. Scharfstein, L. Juliano. 1997. Kininogenase activity by the major cysteinyl proteinase (cruzipain) from Trypanosoma cruzi. J. Biol. Chem. 272: 25713-25718. [Abstract/Free Full Text]
  5. Scharfstein, J., V. Schmitz, V. Morandi, M. M. Capella, A. P. Lima, A. Morrot, L. Juliano, W. Müller-Esterl. 2000. Host cell invasion by Trypanosoma cruzi is potentiated by activation of bradykinin B2 receptors. J. Exp. Med. 192: 1289-1300. [Abstract/Free Full Text]
  6. Lima, A. P., P. C. Almeida, I. L. Tersariol, V. Schmitz, A. H. Schmaier, L. Juliano, I. Y. Hirata, W. Müller-Esterl, J. R. Chagas, J. Scharfstein. 2002. Heparan sulfate modulates kinin release by Trypanosoma cruzi through the activity of cruzipain. J. Biol. Chem. 277: 5875-5881. [Abstract/Free Full Text]
  7. Svensjö, E., P. R. Batista, R. Silva, C. I. Brodskyn, V. Schmitz, E. Saraiva, A. P. C. A. Lima, V. Schmitz, J. B. Pesquero, M. A. S. Mori, et al 2006. Interplay between parasite cysteine proteases and the host kinin system modulates microvascular leakage and macrophage infection by promastigotes of the Leishmania donovani complex. Microbes Infect. 8: 206-220. [Medline]
  8. Leeb-Lundberg, F., F. Marceau, W. Müller-Esterl, D. J. Pettibone, B. L. Zuraw. 2005. Classification of the kinin receptor family: structure, function and regulation. Pharmacol. Rev. 57: 27-77. [Abstract/Free Full Text]
  9. Marceau, F., D. R. Bachvarov. 1998. Kinin receptors. Clin. Rev. Allergy Immunol. 16: 385-401. [Medline]
  10. Shigematsu, S., S. Ishida, D. C. Gute, R. J. Korthuis. 2002. Bradykinin-induced proinflammatory signaling mechanisms. Am. J. Physiol. 283: H2676-H2686.
  11. Shigematsu, S., S. Ishida, D. C. Gute, R. J. Korthuis. 2001. Postischemic anti-inflammatory effects of bradykinin preconditioning. Am. J. Physiol. 280: H441-H454.
  12. Aliberti, J., J. P. Viola, A. Vieira-de-Abreu, P. T. Bozza, A. Sher, J. Scharfstein. 2003. Cutting edge: bradykinin induces IL-12 production by dendritic cells: a danger signal that drives Th1 polarization. J. Immunol. 170: 5349-5353. [Abstract/Free Full Text]
  13. Skidgel, R. A., E. G. Erdös. 2004. Angiotensin converting enzyme (ACE) and neprilysin hydrolyze neuropeptides: a brief history, the beginning and follow-ups to early studies. Peptides 25: 521-525. [Medline]
  14. Blaukat, A., P. Micke, I. Kalatskaya, A. Faussner, W. Müller-Esterl. 2003. Downregulation of bradykinin B2 receptor in human fibroblasts during prolonged agonist exposure. Am. J. Physiol. 284: H1909-H1916.
  15. Danilov, S. M., E. Sadovnikova, N. Scharenborg, I. V. Balyasnikova, D. A. Svinareva, E. L. Semikina, E. N. Parovichnikova, V. G. Savchenko, G. J. Adema. 2003. Angiotensin-converting enzyme (CD143) is abundantly expressed by dendritic cells and discriminates human monocyte-derived dendritic cells from acute myeloid leukemia-derived dendritic cells. Exp. Hematol. 31: 1301-1309. [Medline]
  16. Matzinger, P.. 2002. The danger model: a renewed sense of self. Science 296: 301-305. [Abstract/Free Full Text]
  17. Schnurr, M., F. Then, P. Galambos, C. Scholz, B. Siegmund, S. Endres, A. Eigler. 2000. Extracellular ATP and TNF-{alpha} synergize in the activation and maturation of human dendritic cells. J. Immunol. 165: 4704-4709. [Abstract/Free Full Text]
  18. Srivastava, P.. 2002. Roles of heat-shock proteins in innate and adaptive immunity. Nat. Rev. Immunol. 2: 185-194. [Medline]
  19. Shi, Y., J. E. Evans, K. L. Rock. 2003. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425: 516-521. [Medline]
  20. Basu, S., P. Srivastava. 2005. Immunological role of neuronal receptor vanilloid receptor 1 expressed on dendritic cells. Proc. Natl. Acad. Sci. USA 102: 5120-5125. [Abstract/Free Full Text]
  21. Sporri, R., C. Reis e Sousa. 2005. Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function. Nat. Immunol. 6: 163-170. [Medline]
  22. Iwasaki, A., R. Medzhitov. 2004. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5: 987-995. [Medline]
  23. Marshall, J. S.. 2004. Mast-cell responses to pathogens. Nat. Rev. 4: 787-799.
  24. Todorov, A. G., D. Andrade, J. B. Pesquero, C. Araujo, M. Bader, J. Stewart, L. Gera, W. Müller-Esterl, V. Morandi, R. C. Goldenberg, et al 2003. Trypanosoma cruzi induces edematogenic responses in mice and invades cardiomyocytes and endothelial cells in vitro by activating distinct kinin receptor (B1/B2) subtypes. FASEB J. 17: 73-75. [Abstract/Free Full Text]
  25. Scharfstein, J.. 2003. Activation of bradykinin-receptors by Trypanosoma cruzi: a role for cruzipain in microvascular pathology. J. M. Kelly, ed. Molecular Pathogenesis of Chagas' Disease 111-137. Landes Bioscience, Austin.
  26. Campos, M. A., I. C. Almeida, O. Takeuchi, S. Akira, E. P. Valente, D. O. Procopio, L. R. Travassos, J. A. Smith, D. T. Golenbock, R. T. Gazzinelli. 2001. Activation of Toll-like receptor-2 by glycosylphosphatidylinositol anchors from a protozoan parasite. J. Immunol. 167: 416-423. [Abstract/Free Full Text]
  27. Almeida, I. C., R. T. Gazzinelli. 2001. Proinflammatory activity of glycosylphosphatidylinositol anchors derived from Trypanosoma cruzi: structural and functional analyses. J. Leukocyte Biol. 70: 467-477. [Abstract/Free Full Text]
  28. Ouaissi, A., E. Guilvard, Y. Delneste, G. Caron, G. Magistrelli, N. Herbault, N. Thieblemont, P. Jeannin. 2002. The Trypanosoma cruzi Tc52-released protein induces human dendritic cell maturation, signals via Toll-like receptor 2, and confers protection against lethal infection. J. Immunol. 168: 6366-6374. [Abstract/Free Full Text]
  29. Oliveira, A. C., J. R. Peixoto, L. B. de Arruda, M. A. Campos, R. T. Gazzinelli, D. T. Golenbock, S. Akira, J. O. Previato, L. Mendonca-Previato, A. Nobrega, M. Bellio. 2004. Expression of functional TLR4 confers proinflammatory responsiveness to Trypanosoma cruzi glycoinositolphospholipids and higher resistance to infection with T. cruzi. J. Immunol. 173: 5688-5696. [Abstract/Free Full Text]
  30. Campos, M. A., M. Closel, E. P. Valente, J. E. Cardoso, S. Akira, J. I. Alvarez-Leite, C. Ropert, R. T. Gazzinelli. 2004. Impaired production of proinflammatory cytokines and host resistance to acute infection with Trypanosoma cruzi in mice lacking functional myeloid differentiation factor 88. J. Immunol. 172: 1711-1718. [Abstract/Free Full Text]
  31. Lima, A. P. C. A., F. G. dos Reis, C. Serveau, G. Lalmanach, J. Juliano, R. Menard, T. Vernet, D. Y. Thomas, A. C. Storer, J. Scharfstein. 2001. Recombinant cysteine protease isoforms from Trypanosoma cruzi, cruzipain 2 and cruzain, present different substrate preference and susceptibility to inactivation by inhibitors. Mol. Biochem. Parasitol. 114: 41-52. [Medline]
  32. Almeida, I. C., M. M. Camargo, D. O. Procopio, L. S. Silva, A. Mehlert, L. R. Travassos, R. T. Gazzinelli, M. A. Ferguson. 2000. Highly purified glycosylphosphatidylinositols from Trypanosoma cruzi are potent proinflammatory agents. EMBO J. 19: 1476-1485. [Medline]
  33. Engel, J. C., P. S. Doyle, I. Hsieh, J. H. McKerrow. 1998. Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection. J. Exp. Med. 188: 725-734. [Abstract/Free Full Text]
  34. Riedemann, N. C., R. F. Guo, T. J. Hollmann, H. Gao, T. A. Neff, J. S. Reuben, C. L. Speyer, J. V. Sarma, R. A. Wetsel, F. S. Zetoune, P. A. Ward. 2004. Regulatory role of C5a in LPS-induced IL-6 production by neutrophils during sepsis. FASEB J. 18: 370-372. [Abstract/Free Full Text]
  35. Scharfstein, J.. 2006. Parasite cysteine proteinase interactions with {alpha} 2-macroglobulin or kininogens: differential pathways modulating inflammation and innate immunity in infection by pathogenic trypanosomatids. Immunobiology 211: 117-125. [Medline]
  36. Coelho, P. S., A. Klein, A. Talvani, S. F. Coutinho, O. Takeuchi, S. Akira, J. S. Silva, H. Canizzaro, R. T. Gazzinelli, M. M. Teixeira. 2002. Glycosylphosphatidylinositol-anchored mucin-like glycoproteins isolated from Trypanosoma cruzi trypomastigotes induce in vivo leukocyte recruitment dependent on MCP-1 production by IFN-{gamma}-primed-macrophages. J. Leukocyte Biol. 71: 837-844. [Abstract/Free Full Text]
  37. Tarleton, R. L.. 2003. Chagas disease: a role for autoimmunity?. Trends Parasitol. 19: 447-451. [Medline]
  38. Gautam, N., A. M. Olofsson, H. Herwald, L. F. Iversen, E. Lundgren-Akerlund, P. Hedqvist, K. E. Arfors, H. Flodgaard, L. Lindbom. 2001. Heparin-binding protein (HBP/CAP37): a missing link in neutrophil-evoked alteration of vascular permeability. Nat. Med. 7: 1123-1127. [Medline]
  39. Fan, J., R. S. Frey, A. B. Malik. 2003. TLR4 signaling induces TLR2 expression in endothelial cells via neutrophil NADPH oxidase. J. Clin. Invest. 112: 1234-1243. [Medline]
  40. Ferreira, J., G. L. da Silva, J. B. Calixto. 2004. Contribution of vanilloid receptors to the overt nociception induced by B2 kinin receptor activation in mice. Br. J. Pharmacol. 141: 787-794. [Medline]



This article has been cited by other articles:


Home page
 J. Leukoc. Biol.Home page
V. Schmitz, E. Svensjo, R. R. Serra, M. M. Teixeira, and J. Scharfstein
Proteolytic generation of kinins in tissues infected by Trypanosoma cruzi depends on CXC chemokine secretion by macrophages activated via Toll-like 2 receptors
J. Leukoc. Biol., June 1, 2009; 85(6): 1005 - 1014.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Monteiro, A. C.
Right arrow Articles by Scharfstein, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Monteiro, A. C.
Right arrow Articles by Scharfstein, J.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS